Vera Therapeutics, Inc. (VERA) earnings date
Mar 10, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 36 days, typically, give or take 9 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Mon, Aug 10, 2026 | after close | 41 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Wed, Nov 5, 2025 | before open | 36 | 8-K |
| Q2 FY2025 | Tue, Aug 5, 2025 | before open | 36 | 8-K |
| Q1 FY2025 | Tue, May 6, 2025 | before open | 36 | 8-K |
| Q4 FY2024 | Wed, Feb 26, 2025 | before open | 57 | 8-K |
What they guided beta
| Q3 FY2026 | "Potential full approval of TRUTAKNA in adults with primary IgAN, subject to FDA review of the sBLA, expected in mid-2027." exhibit |
| Q3 FY2026 | "Planned Marketing Authorisation Application submission to the European Medicines Agency expected in Q1 2027 for standard marketing authorisation." exhibit |
| Q2 FY2026 | "Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026." exhibit |
| Q2 FY2026 | "Anticipated supplemental Biologics License Application (sBLA) submission to the FDA – expected in Q4 2026." exhibit |
| Q2 FY2026 | "Final efficacy analysis from the ORIGIN 3 trial expected in Q3 2026" exhibit |
| Q2 FY2026 | "Anticipated sBLA submission to the FDA expected in Q4 2026" exhibit |
| Q2 FY2026 | "Additional PIONEER clinical results expected in Q4 2026" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/VERA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/VERA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/VERA/"><img src="https://veritasdata.dev/embed/VERA.svg" alt="VERA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/VERA/)
Script
<script async src="https://veritasdata.dev/embed/VERA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/VERA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.